Evolutionary Genomics's quarterly market cap
stayed the same
from Jun. 2022 ($4.66 Mil) to Sep. 2022 ($4.66 Mil) and
stayed the same
from Sep. 2022 ($4.66 Mil) to Dec. 2022 ($4.66 Mil).
Evolutionary Genomics's annual market cap
declined
from Dec. 2020 ($6.47 Mil) to Dec. 2021 ($4.12 Mil) but then
increased
from Dec. 2021 ($4.12 Mil) to Dec. 2022 ($4.66 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Evolutionary Genomics's Enterprise Value for Today is $5.01 Mil.
Evolutionary Genomics (OTCPK:FNAM) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Evolutionary Genomics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolutionary Genomics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Market Cap distribution charts can be found below:
* The bar in red indicates where Evolutionary Genomics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Evolutionary Genomics's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolutionary Genomics (FNAM) has a Market Cap of $0.00 Mil as of Jul. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Evolutionary Genomics and its competitors.
Is Evolutionary Genomics' Market Cap too high?
Evolutionary Genomics' current Market Cap is $0.00 Mil. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' Market Cap compare to BXRX and GNCA?
Evolutionary Genomics' Market Cap of $0.00 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 119.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.31, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Evolutionary Genomics and its competitors. For the Biotechnology industry, the median Market Cap is 119.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolutionary Genomics's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current Market Cap is $0.00 Mil as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score
Get the complete analysis for FNAM
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FNAM has been successfully added to your 
